12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ganetespib: Phase II data

Data from the first stage of an open-label Phase II trial showed that ganetespib missed the pre-specified criteria of >=3 responses in 22 patients with metastatic breast cancer. Specifically, ganetespib produced 2 partial responses, plus 7 cases of stable disease. The 2 partial responses and 6 of the cases of stable disease occurred in 13 patients with HER2-positive triple-negative breast cancer (TNBC) refractory...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >